2020
Ba HL, Mbatchi L, Gattacceca F, Evrard A, Lacarelle B, Blanchet B, Ciccolini J, Salas S.
Ferrer F, Solas C, Giocanti M, Lacarelle B, Deville JL, Gravis G, Ciccolini J.
Surun A, Varlet P, Brugières L, Lacour B, Faure-Conter C, Leblond P, Bertozzi-Salomon AI, Berger C, André N, Sariban E, Raimbault S, Prieur F, Desseigne F, Zattara H, Guimbaud R, Polivka M, Delisle MB, Vasiljevic A, Maurage CA, Figarella-Branger D, Coulet F, Guerrini-Rousseau L, Alapetite C, Dufour C, Colas C, Doz F, Bourdeaut F.
?
?
2019
Yamasaki T, Buric D, Chacon C, Audran G, Braguer D, Marque SRA, Carré M, Brémond P.
Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters.
Deyme L, Barbolosi D, Gattacceca F.
Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?
Peters GJ, Giovannetti E, Honeywell RJ, Ciccolini J.
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors.
Centanni M, Moes DJAR, Trocóniz IF, Ciccolini J, van Hasselt JGC.
Structural identifiability and sensitivity.
Iliadis A.
de Nonneville A, Barbolosi D, Andriantsoa M, El-Cheikh R, Duffaud F, Bertucci F, Salas S.
Veal GJ, Amankwatia EB, Paludetto MN, Möcklinghoff T, Thomson F, André N, Ciccolini J, Chatelut E.
Sousa F, Dhaliwal HK, Gattacceca F, Sarmento B, Amiji MM.
Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer.
Schneider BK, Boyer A, Ciccolini J, Barlesi F, Wang K, Benzekry S, Mochel JP.
Néant N, Solas C, Bouazza N, Lê MP, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Gattacceca F.
Rodallec A, Fanciullino R, Benzekry S, Ciccolini J; EORTC PAMM Group.
Donnette M, Solas C, Giocanti M, Venton G, Farnault L, Berda-Haddad Y, Hau LTT, Costello R, Ouafik L, Lacarelle B, Ciccolini J, Fanciullino R.
Gbeto CC, Quaranta S, Mari R, Fanciullino R, Roche C, Nahon S, Solas C, Ouafik L, Lacarelle B, Allegre T, Ciccolini J.
Rodallec A, Sicard G, Giacometti S, Carre M, Maia T, Valette M, Bouquet F, Savina A, Lacarelle B, Ciccolini J, Fanciullino R.
Bilous M, Serdjebi C, Boyer A, Tomasini P, Pouypoudat C, Barbolosi D, Barlesi F, Chomy F, Benzekry S.
Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess.
Ciccolini J, Barbolosi D, André N, Benzekry S, Barlesi F.
Moeung S, Chevreau C, Poinsignon V, Guitton J, Lelièvre B, Ciccolini J, Gladieff L, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Delahousse J, Filleron T, Lochon I, Chatelut E, Thomas F.
2018
Padovani L, Chapon F, André N, Boucekine M, Geoffray A, Bourdeau F, Masliah-Planchon J, Claude L, Huchet A, Laprie A, Supiot S, Coche-Dequéant B, Kerr C, Alapetite C, Leseur J, Nguyen T, Chapet S, Bernier V, Bondiau PY, Noel G, Habrand JL, Bolle S, Doz F, Dufour C, Muracciole X, Carrie C.
Verschuur A, Heng-Maillard MA, Dory-Lautrec P, Truillet R, Jouve E, Chastagner P, Leblond P, Aerts I, Honoré S, Entz-Werle N, Sirvent N, Gentet JC, Corradini N, André N.
“Hard” Drug Repurposing for Precision Oncology: The Missing Link?
Pantziarka P, Bouche G, André N.
Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles.
Rodallec A, Fanciullino R, Lacarelle B, Ciccolini J.
Rodallec A, Brunel JM, Giacometti S, Maccario H, Correard F, Mas E, Orneto C, Savina A, Bouquet F, Lacarelle B, Ciccolini J, Fanciullino R.
Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N, Barlesi F, Mascaux C.
Fanciullino R, Farnault L, Donnette M, Imbs DC, Roche C, Venton G, Berda-Haddad Y, Ivanov V, Ciccolini J, Ouafik L, Lacarelle B, Costello R.
Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC.
Imbs DC, El Cheikh R, Boyer A, Ciccolini J, Mascaux C, Lacarelle B, Barlesi F, Barbolosi D, Benzekry S.
Fabresse N, Devictor B, Pissier C, Chambost H, Lacarelle B, Michel G, Solas C.
Néant N, Gattacceca F, Lê MP, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Solas C.
Rodallec A, Sicard G, Giacometti S, Carré M, Pourroy B, Bouquet F, Savina A, Lacarelle B, Ciccolini J, Fanciullino R.
Rodallec A, Sicard G, Fanciullino R, Benzekry S, Lacarelle B, Milano G, Ciccolini J.
Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology.
Rodallec A, Benzekry S, Lacarelle B, Ciccolini J, Fanciullino R.
Madelain V, Baize S, Jacquot F, Reynard S, Fizet A, Barron S, Solas C, Lacarelle B, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X, Guedj J.
“No pain, No gain” still true with immunotherapy: When the finger shows the moon, look at the moon!
Milano G, Innocenti F, Lacarelle B, Ciccolini J.
Immunologically effective dose: a practical model for immuno-radiotherapy.
Serre R, Barlesi F, Muracciole X, Barbolosi D.
Barbolosi D, Crona J, Serre R, Pacak K, Taieb D.
2017
PRIMUM NON NOCERE: now and again an echo of DPD with capecitabine.
Ciccolini J, Lacarelle B, Milano G
Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study.
Moeung S, Chevreau C, Broutin S, Guitton J, Lelièvre B, Ciccolini J, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Paci A, Marsili S, Malard L, Chatelut E, Thomas F.
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing.
Etienne-Grimaldi MC, Le Guellec CB, Boyer JC, Chatelut E, Evrard A, Loriot MA, Paci A, Royer B, Thomas F, Ciccolini J.
Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy.
Ciccolini J, Barbolosi D, Meille C, Lombard A, Serdjebi C, Giacometti S, Padovani L, Pasquier E, André N.
A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients.
Becher F, Ciccolini J, Imbs DC, Marin C, Fournel C, Dupuis C, Fakhry N, Pourroy B, Ghettas A, Pruvost A, Junot C, Duffaud F, Lacarelle B, Salas S.
Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients.
Barlesi F, Imbs DC, Tomasini P, Greillier L, Galloux M, Testot-Ferry A, Garcia M, Elharrar X, Pelletier A, André N, Mascaux C, Lacarelle B, Cheikh RE, Serre R, Ciccolini J, Barbolosi D.
Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis.
Mollard S, Ciccolini J, Imbs DC, El Cheikh R, Barbolosi D, Benzekry S.
Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach.
Serdjebi C, Gattacceca F, Seitz JF, Fein F, Gagnière J, François E, Abakar-Mahamat A, Deplanque G, Rachid M, Lacarelle B, Ciccolini J, Dahan L.
Mathematical Modeling of Tumor-Tumor Distant Interactions Supports a Systemic Control of Tumor Growth.
Benzekry S, Lamont C, Barbolosi D, Hlatky L, Hahnfeldt P.
Modeling therapeutic response to radioiodine in metastatic thyroid cancer: a proof-of-concept study for individualized medicine.
Barbolosi D, Summer I, Meille C, Serre R, Kelly A, Zerdoud S, Bournaud C, Schvartz C, Toubeau M, Toubert ME, Keller I, Taïeb D.
Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients.
Faivre C, El Cheikh R, Barbolosi D, Barlesi F.
Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration.
Bregigeon S, Solas C, Faucher O, Obry-Roguet V, Tamalet C, Poizot-Martin I.
Daclatasvir plasma concentration assessment in HIV-HCV-coinfected real-life patients.
Taton A, Colson P, Dhiver C, Ruiz JM, Bregigeon S, Tomei C, Ressiot E, Menard A, Poizot-Martin I, Ravaux I, Lacarelle B, Solas C.
Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe.
Menard A, Montagnac C, Solas C, Meddeb L, Dhiver C, Tomei C, Ravaux I, Tissot-Dupont H, Mokhtari S, Colson P, Stein A.
Sub-therapeutic darunavir concentration and garlic consumption; a «Mediterranean» drug-food interaction, about 2 cases.
Cloarec N, Solas C, Ladaique A, Tamalet C, Zaegel-Faucher O, Bregigeon S, Canet B, Cano CE, Poizot-Martin I.
Severe neurological disorders and refractory aspergillosis in an adolescent treated by vincristine and voriconazole.
Bennis Y, Bodeau S, Lutun A, Gourmel A, Solas C, Quaranta S, Guillaume N, Chouaki T, Lemaire-Hurtel AS, Masmoudi K.
Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety.
Solas C, Bregigeon S, Faucher-Zaegel O, Quaranta S, Obry-Roguet V, Tamalet C, Lacarelle B, Poizot-Martin I.
Population pharmacokinetics model of THC used by pulmonary route in occasional cannabis smokers.
Marsot A, Audebert C, Attolini L, Lacarelle B, Micallef J, Blin O.
Visual compatibility of blinatumomab with selected drugs during simulated Y-site administration.
Du Repaire T, Vigne P, Guedon A, Fanciullino R, Gauthier-Villano L, Peres PB, Pourroy B.
Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?
André N, Tsai K, Carré M, Pasquier E.
Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.
Le Grand M, Berges R, Pasquier E, Montero MP, Borge L, Carrier A, Vasseur S, Bourgarel V, Buric D, André N, Braguer D, Carré M.
2016
Mollard S, Fanciullino R, Giacometti S, Serdjebi C, Benzekry S, Ciccolini J.
Collery P, Santoni F, Ciccolini J, Tran TN, Mohsen A, Desmaele D.
Prevention of fluoropyrimidine toxicity: do we still have to try our patient’s luck?
Danesi R, Del Re M, Ciccolini J, Schellens JHM, Schwab M, van Schaik RHN, van Kuilenburg ABP.
Gouri A, Dekaken A, El Bairi K, Aissaoui A, Laabed N, Chefrour M, Ciccolini J, Milano G, Benharkat S.
Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy.
Serre R, Benzekry S, Padovani L, Meille C, André N, Ciccolini J, Barlesi F, Muracciole X, Barbolosi D.
Women at a Disadvantage in Fluorouracil Treatment.
Ciccolini J, Milano G..
Nucleoside analogs: ready to enter the era of precision medicine?
Ciccolini J, Serdjebi C, Le Thi Thu H, Lacarelle B, Milano G, Fanciullino R.
Elharrar X, Barbolosi D, Ciccolini J, Meille C, Faivre C, Lacarelle B, André N, Barlesi F.
Padovani L, Baret A, Ciccolini J, Taieb D, Bardia F, Teissonnier L, Muracciole X, Barlesi F, Barbolosi D.
Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E.
Monoclonal antibodies for treating gastric cancer: promises and pitfalls.
Sibertin-Blanc C, Ciccolini J, Norguet E, Lacarelle B, Dahan L, Seitz JF.
Meille C, Barbolosi D, Ciccolini J, Freyer G, Iliadis A.
Meille C, Barbolosi D, Ciccolini J, Freyer G, Iliadis A.
Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia.
Venton G, Adam H, Colle J, Labiad Y, Mercier C, Ivanov V, Suchon P, Fanciullino R, Farnault L, Costello R.
Menard A, Colson P, Catherine D, Isabelle R, Christelle T, Meddeb L, Ben Ali S, Solas C, Stein A.
Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, Renault A, Bourlière M, Halfon P, Ghosn J, Alric L, Naqvi A, Carrieri P, Molina JM; ANRS HC27 BOCEPREVIH Study Group.
Kheloufi F, Bellissant E, Cotte L, Poizot-Martin I, Quaranta S, Garraffo R, Barrail-Tran A, Renault A, Fournier I, Lacarelle B, Bourlière M, Molina JM, Solas C
Poizot-Martin I, Brégigeon S, Tamalet C, Bouabdallah R, Zaegel-Faucher O, Obry-Roguet V, Ivanova A, Cano CE, Solas C.
Kheloufi F, Poizot-Martin I, Garraffo R, Tavenard A, Quaranta S, Renault A, Lavrut T, Bourlière M, Halfon P, Piroth L, Bellissant E, Lacarelle B, Molina JM, Solas C; ANRS HC27 BOCEPREVIH Study Group.
Marsot A, Audebert C, Attolini L, Lacarelle B, Micallef J, Blin O.